BOSTON and TEL-AVIV, Israel, Jan. 11, 2022 (GLOBE NEWSWIRE) — Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced the final close of $28 million in seed funding – inclusive of the initial $9 million announced late last year with the launch of Quris’ BioAI platform for clinical prediction. Led by Welltech Ventures with participation from iAngels, GlenRock Capital, and others, the funding will fast-track Quris’ novel drug research and development, team expansion and partner-building efforts as it scales to rapidly scan 100s of drug candidates to train its AI engine in its mission to revolutionize the drug development process.

Since launching its clinical prediction AI platform late last year, Quris has focused on expanding its industry collaborations and prepping the first drug developed on the platform, addressing Fragile X syndrome (FXS), for clinical testing in 2022.

“With an exemplary team and remarkable technology breakthroughs, Quris fit perfectly into our portfolio of health and wellness technology innovators,” said Amir Alroy and Galit Horovitz, co-founders of Welltech Ventures. “We are thrilled to take the lead in the company’s seed round, as we think Quris is primed to forge the next critical phase in novel drug discovery and its AI platform will also help the industry rethink how and when to best use existing drugs.”